Clinical Trials Logo

Clinical Trial Summary

This protocol offers diagnosis and standard medical treatment for various parasitic gastrointestinal infections. Gastrointestinal parasites are either worms (helminths) or one-celled animals called protozoans which live in the human intestines. Often, parasitic infections do not cause illness. In these cases, drug treatment is not indicated, because treatment can have adverse side effects. Patients will be examined for their immune responses, correlation between the number of parasites and disease, and other studies.

Individuals with known or suspected parasitic diseases of the gastrointestinal tract, including amebiasis, giardiasis, hookworm, strongyloidiasis, trichuriasis, pinworm, tapeworm, trichinosis, clonorchis, opisthorchis, coccidiosis, paragonimiasis, and echinococcus may be eligible for this study.

Patient evaluations may include blood and urine tests, stool examination, X-rays, ultrasound studies and, uncommonly, duodenal aspiration for examination of fluid from the duodenum (first part of the small intestine). Other tests may be required, depending on the parasite and disease. Direct examination of the tissues of the intestines may be required to rule out certain infections.

Research procedures include collection of stool, blood and duodenal fluid when the diagnosis has been established and these procedures are not required for medical care. Patients with strongyloidiasis may also be given a diagnostic skin test similar to skin tests for tuberculosis and allergies. Research procedures on children will be limited to collection of stool, urine and blood. No more than 7 milliliters (1 1/2 teaspoons) per kilogram (2.2 pounds) body weight of blood will be collected in children over a 6-week period. In adults no more than 30 tablespoons of blood will be collected in a 6-week period.

Parasites may fail to respond to treatment. In these cases, it may be necessary to grow the parasite in the laboratory in order to test treatments in the test tube. Patients who do not respond to standard medications and dosing may need different doses of drugs or drugs or combinations of drugs used in the United States for other medical problems. If these medications or doses are used, patients will be informed of their possible side effects.


Clinical Trial Description

The precis of this protocol is to allow the evaluation, treatment and study of patients with a variety of gastrointestinal parasites. This protocol primarily allows evaluation and treatment of patients with any intestinal parasite that requires a medical evaluation. The treatment and evaluation consists of standard of care. Research aspects include the collection and study of different parasite populations, analysis of the immune responses of the host, a correlation between parasite burden in the host and disease. These patients also serve as a source of reagents such as feces, white blood cells, and serum. The off-label use of FDA approved drugs is employed to treat symptomatic giardiasis in patients who cannot be cured otherwise and to determine empirically which regimens are effective and safe. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00001162
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase N/A
Start date May 23, 1977
Completion date May 31, 2017

See also
  Status Clinical Trial Phase
Terminated NCT00057486 - Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients Phase 1/Phase 2
Completed NCT00507871 - Transmission and the Respiratory Tract in Cryptosporidiosis N/A
Recruiting NCT05208970 - Cryptosporidium Species in Sohag Governorate
Recruiting NCT04332705 - Cryptosporidium Infection and Human Colorectal Cancer
Active, not recruiting NCT02764918 - Cryptosporidiosis and Enteropathogens in Bangladesh
Not yet recruiting NCT01695304 - Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya N/A
Terminated NCT00004986 - Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Phase 3
Completed NCT04103216 - Treatment of Cryptosporidiosis N/A
Terminated NCT03341767 - A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Phase 2
Completed NCT01699841 - Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events N/A
Active, not recruiting NCT00002158 - A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis N/A
Completed NCT00000771 - A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Phase 2
Completed NCT00002082 - Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study N/A
Completed NCT00002328 - Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs N/A
Completed NCT00002027 - Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) N/A
Completed NCT00000980 - A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea Phase 1
Completed NCT00001018 - A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea Phase 1
Completed NCT00002264 - The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea N/A
Completed NCT00002248 - A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Phase 1
Completed NCT00055107 - Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Phase 1/Phase 2